PA8481901A1 - ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER - Google Patents

ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER

Info

Publication number
PA8481901A1
PA8481901A1 PA19998481901A PA8481901A PA8481901A1 PA 8481901 A1 PA8481901 A1 PA 8481901A1 PA 19998481901 A PA19998481901 A PA 19998481901A PA 8481901 A PA8481901 A PA 8481901A PA 8481901 A1 PA8481901 A1 PA 8481901A1
Authority
PA
Panama
Prior art keywords
active agent
administration
dry powder
inhibitor
hygroscopic growth
Prior art date
Application number
PA19998481901A
Other languages
Spanish (es)
Inventor
Barry John Aldous
Andrew Clark
Kuo Mei Chang
Cecily Lalor
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of PA8481901A1 publication Critical patent/PA8481901A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

PARTICULAS PARA LA ADMINISTRACION DE UN AGENTE ACTIVO A LOS ALVEOLOS DE UN PACIENTE HUMANO, PARTICULAS QUE CONTIENEN EL AGENTE ACTIVO Y UN INHIBIDOR DEL CRECIMIENTO HIGROSCOPICO, DONDE EL INHIBIDOR DEL CRECIMIENTO HIGROSCOPICO ESTA INCORPORADO AL INTERIOR DE LAS PARTICULAS Y DONDE LAS PARTICULAS EXHIBEN UNA CAIDA DE LA DOSIS EMITIDA, EN CONDICIONES PULMONARES SIMULADAS, DE NO MAS DE APROXIMADAMENTE 25%.PARTICLES FOR THE ADMINISTRATION OF AN ACTIVE AGENT TO THE HELLS OF A HUMAN PATIENT, PARTICLES CONTAINING THE ACTIVE AGENT AND AN INHIBITOR OF HYGROSCOPIC GROWTH, WHERE THE INHIBITOR OF HYGROSCOPIC GROWTH IS INCORPORATED TO THE INSIDE OF PARTICULAS THE DOSE ISSUED, IN SIMULATED PULMONARY CONDITIONS, OF NO MORE THAN APPROXIMATELY 25%.

PA19998481901A 1998-09-14 1999-09-14 ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER PA8481901A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
PA8481901A1 true PA8481901A1 (en) 2002-04-25

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998481901A PA8481901A1 (en) 1998-09-14 1999-09-14 ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER

Country Status (44)

Country Link
EP (1) EP1117442A1 (en)
JP (1) JP2002524535A (en)
KR (1) KR20010075063A (en)
CN (1) CN1317977A (en)
AP (1) AP1374A (en)
AR (1) AR022090A1 (en)
AU (1) AU753014B2 (en)
BG (1) BG105430A (en)
BR (1) BR9913722A (en)
CA (1) CA2343920A1 (en)
CO (1) CO5130023A1 (en)
CZ (1) CZ2001829A3 (en)
DZ (1) DZ2892A1 (en)
EA (1) EA003476B1 (en)
EE (1) EE200100151A (en)
GE (1) GEP20043257B (en)
GT (1) GT199900156A (en)
HK (1) HK1042231A1 (en)
HN (1) HN1999000159A (en)
HR (1) HRP20010189A2 (en)
HU (1) HUP0103837A3 (en)
ID (1) ID28845A (en)
IL (2) IL141562A0 (en)
IS (1) IS5878A (en)
LT (1) LT4897B (en)
LV (1) LV12658B (en)
MA (1) MA25590A1 (en)
MY (1) MY129282A (en)
NO (1) NO20011251L (en)
NZ (1) NZ510168A (en)
OA (1) OA11781A (en)
PA (1) PA8481901A1 (en)
PE (1) PE20001061A1 (en)
PL (1) PL195574B1 (en)
SA (1) SA99200718B1 (en)
SK (1) SK3442001A3 (en)
TN (1) TNSN99173A1 (en)
TR (1) TR200101182T2 (en)
TW (1) TWI226248B (en)
UA (1) UA76085C2 (en)
UY (1) UY25711A1 (en)
WO (1) WO2000015262A1 (en)
YU (1) YU24201A (en)
ZA (1) ZA200101995B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198593C (en) 1999-06-09 2005-04-27 罗伯特·E·希弗斯 Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
CN1671643B (en) 2002-02-25 2013-05-29 扩散药品有限公司 Bipolar trans carotenoid salts and their uses
WO2004004798A2 (en) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
MXPA05006802A (en) * 2002-12-19 2005-09-08 Pharmacia Corp Non-hygroscopic formulation comprising a hydroscopic drug.
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MXPA06012240A (en) 2004-04-23 2007-01-31 Cydex Inc Dpi formulation containing sulfoalkyl ether cyclodextrin.
EP2540696B1 (en) * 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
KR20070110418A (en) * 2005-03-09 2007-11-16 오노 야꾸힝 고교 가부시키가이샤 Particle and preparation containing the particle
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
MX348982B (en) 2005-10-26 2017-07-06 Cydex Pharmaceuticals Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof.
US20100269819A1 (en) * 2006-08-14 2010-10-28 Sievers Robert E Human Powered Dry Powder Inhaler and Dry Powder Inhaler Compositions
US20100093875A1 (en) * 2006-10-25 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
EP3483140A1 (en) 2007-04-13 2019-05-15 Diffusion Pharmaceuticals LLC Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
CN101878040A (en) 2007-10-31 2010-11-03 扩散药品有限公司 A new class of therapeutics that enhance small molecule diffusion
US9610343B2 (en) * 2009-05-20 2017-04-04 Aeras Global Tb Vaccine Foundation Stable, spray dryed, immunogenic, viral compositions
CN108464976A (en) 2009-06-22 2018-08-31 扩散药品有限公司 Diffusion promotes compound and its independent or application together with Thrombolytic Drugs
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
JP6349304B2 (en) 2012-05-03 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー Polyinosine-polycytidylic acid (poly (I: C)) formulation for the treatment of upper respiratory tract infections
BR112015010601B1 (en) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
KR102489034B1 (en) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 Use of Bipolar Trans Carotenoids with Chemotherapy and Radiation Therapy to Treat Cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
NZ510168A (en) 2003-09-26
WO2000015262A1 (en) 2000-03-23
EA003476B1 (en) 2003-06-26
LV12658A (en) 2001-05-20
IL141562A (en) 2007-07-24
EA200100300A1 (en) 2001-10-22
AP1374A (en) 2005-02-28
KR20010075063A (en) 2001-08-09
TNSN99173A1 (en) 2005-11-10
ID28845A (en) 2001-07-05
OA11781A (en) 2005-07-26
BG105430A (en) 2001-12-29
HK1042231A1 (en) 2002-08-09
TR200101182T2 (en) 2001-09-21
AR022090A1 (en) 2002-09-04
UA76085C2 (en) 2006-07-17
EE200100151A (en) 2002-06-17
AP2001002093A0 (en) 2001-03-31
SK3442001A3 (en) 2001-11-06
BR9913722A (en) 2001-05-29
HN1999000159A (en) 1999-11-11
CZ2001829A3 (en) 2001-09-12
HRP20010189A2 (en) 2005-04-30
MY129282A (en) 2007-03-30
YU24201A (en) 2003-08-29
EP1117442A1 (en) 2001-07-25
DZ2892A1 (en) 2003-12-15
GEP20043257B (en) 2004-06-25
CA2343920A1 (en) 2000-03-23
AU753014B2 (en) 2002-10-03
IL141562A0 (en) 2002-03-10
PL346768A1 (en) 2002-02-25
TWI226248B (en) 2005-01-11
LT4897B (en) 2002-02-25
PE20001061A1 (en) 2000-10-08
PL195574B1 (en) 2007-10-31
LV12658B (en) 2001-09-20
MA25590A1 (en) 2002-12-31
AU6039799A (en) 2000-04-03
CN1317977A (en) 2001-10-17
NO20011251D0 (en) 2001-03-13
GT199900156A (en) 2001-03-07
CO5130023A1 (en) 2002-02-27
ZA200101995B (en) 2002-03-11
SA99200718B1 (en) 2006-11-04
LT2001021A (en) 2001-11-26
HUP0103837A3 (en) 2002-11-28
IS5878A (en) 2001-03-05
UY25711A1 (en) 1999-11-17
HUP0103837A2 (en) 2002-05-29
JP2002524535A (en) 2002-08-06
NO20011251L (en) 2001-04-17

Similar Documents

Publication Publication Date Title
PA8481901A1 (en) ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER
CO5060522A1 (en) ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL
ES2159591T3 (en) COMPOSITION OF CONTROLLED RELEASE.
GT200000041A (en) USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES.
ES2073205T3 (en) AGENTS WITH PHYSIOLOGICAL REFRIGERATING EFFECT AND PROPER ACTIVE COMPOUNDS FOR THESE AGENTS.
AR002754A1 (en) PHARMACEUTICAL COMPOSITION COMPRISING MICRO-ENCAPSULATED VIABLE LACTOBACILLUS BACTERIA, AND USE OF THE COMPOSITION TO PREPARE A MEDICINAL PRODUCT
ES2117015T3 (en) COMPOSITIONS CONTAINING SUMATRIPTAN.
ES2064121T3 (en) AGENT TO REDUCE OR ELIMINATE THE GROWTH OF HAIR IN THE HUMAN BODY.
MX9300620A (en) PHARMACEUTICAL FORMULATION IN AEROSOL AND INHALER FOR THE ADMINISTRATION OF BECLOMETASONE DIPROPIONATE.
ES2082288T3 (en) THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF KETOROLACO.
GT199900164AA (en) CONSUMABLE FILM THAT ADHESES AND DISSOLVES IN THE MOUTH OF A CONSUMER.
BRPI0408655A (en) formulations comprising an active agent and cocoa powder and their use
DE69620606D1 (en) FIXED ORAL APPLICATION FORM
BRPI0313148B8 (en) solid matrix formulations of lamotrigine containing outer coating and perforation in such coating
BR0311460A (en) Modified release pharmaceutical composition, use of a formulation, and method for treating a cardiovascular disorder in a patient
NO951498L (en) Pharmaceutical preparation for the treatment of osteoporosis
ES2184145T3 (en) SULPHONIC ACID OR SULFONYLAMINE ACIDS-N- (HETEROARALQUIL) -AZAHETEROCICLILAMIDA.
AR024998A1 (en) NEW RETINOIDS FOR THE TREATMENT OF THE DISEASE
CN111214689A (en) Sachet for efficiently preventing novel coronavirus pneumonia and influenza
ES2179960T3 (en) CONSERVATION SOLUTION FOR ORGANS OR FABRICS, OR PARTS OF THE SAME, OF HUMAN OR ANIMAL BEINGS.
EA200200151A1 (en) DRY POWDER COMPOSITION
CO5580741A2 (en) PHARMACEUTICAL COMPOSITION INCLUDING A 5HT1 RECEIVER AGONIST
AR021086A1 (en) OMEGA-AMIDAS OF N-ARILSULFONIL-AMINO ACIDS, A PROCEDURE FOR THE PREPARATION, MEDICATION, USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PROCEDURE FOR THE PREPARATION OF A MEDICINAL PRODUCT.
ES2176495T3 (en) USE OF AN BRADIQUININE ANTAGONIST, INTENDED TO INDUCE AND / OR STIMULATE THE GROWTH OF HAIRS AND / OR STOP THEIR FALL.
AR026254A1 (en) THE USE OF A CONTROLLED RELEASE PREPARATION FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INCREASE THE DOSE OR SYSTEM EXPOSURE OF A PHARMACO THAT INHIBITS PHOSPHODESTERASE 4